Resources Repository
-
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Technology Assessment | Cost-Effectiveness Analysis | North America | Priority Setting/Ethics | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Technology Assessment | Cost-Effectiveness Analysis | North America | Preferences/Values | Health Outcomes | Evidence Synthesis | Chronic Disease/Risk | Mental Health | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | North America | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
Cost-Effectiveness Analysis | North America | Mathematical Models | State-Transition | Chronic Disease/Risk | Clinical Care | Health/Medicine -
ArticlePublication 2023Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older …
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older hypertensive patients between 60 and 80 years in China, the US, and the UK. Treatment outcome data from the Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP trial) and different cardiovascular risk assessment models for a hypothetical cohort of STEP-eligible patients were used. Costs and utilities were obtained from published sources. A Markov model was used to…
Cost-Effectiveness Analysis | North America | Mathematical Models | Chronic Disease/Risk | Clinical Care -
Resource PackWeb Portal, Teaching Resource 2023Resource Pack: Cost-Effectiveness of Screening and Treatment for Hypertension
Hypertension is a relevant example for teaching clinical decision making, diagnostic test performance, positivity criterion, …
Hypertension is a relevant example for teaching clinical decision making, diagnostic test performance, positivity criterion, and cost-effectiveness analysis. This resource pack provides examples of decision analyses and cost-effectiveness analyses for the management and treatment of hypertension, with a predominant focus on the U.S. Analyses are included that predate the 2017 American College of Cardiology/American Heart Association Clinical Practice Guidelines, along with more recent examples that followed release of the guidelines. Resources are also included that…
Cost-Effectiveness Analysis | North America | Preferences/Values | Test Performance | Decision Analysis | Chronic Disease/Risk | Clinical Care | Economics/Finance | Health/Medicine | Science/Technology | Europe | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
ArticlePublication 2022Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 …
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 billion in March 2021 for testing in schools. The study aimed to analyze the costs and benefits of different COVID-19 testing strategies, particularly focusing on full-time, in-person elementary and middle school education. Utilizing an updated agent-based network model, the study simulated transmission scenarios in schools, considering various testing strategies ranging from diagnostic testing (test-to-stay) to reduce symptom-based isolations, routine screening…
Cost-Effectiveness Analysis | North America | Test Performance | Mathematical Models | Infectious Diseases | Clinical Care | Health/Medicine | Science/Technology -
EditorialPublication 2021Scientific and Regulatory Challenges in Designing mHealth Interventions
Scientists looking for innovative ways to deliver health care have long searched for mechanisms that …
Scientists looking for innovative ways to deliver health care have long searched for mechanisms that can enable the right intervention to be delivered at the right time. Traditional delivery mechanisms have been limited both to the availability of a provider (e.g., a physician) and the location of care (e.g., a hospital or outpatient clinic). In recent years, however, numerous technological advancements—including wearable devices, mobile technologies, and the widespread development and use of user-friendly smartphone applications—have…
Technology Assessment | North America | Health/Medicine | Science/Technology -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Cost-Effectiveness Analysis | North America | Priority Setting/Ethics | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | Health/Medicine | Global